GSK plc at JPMorgan Healthcare Conference Transcript
Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the GSK presentation. You're going to hear from GSK, CEO, Emma Walmsley, and we can have the Q&A after in this presentation room. So thanks a lot for joining us today. Emma looking forward to the presentation.
Thank you very much, James. Good morning, good afternoon to anyone that's watching a very happy new year to you all. And let me say, of course, how absolutely wonderful it is to be able to attend today's conference in person.
Please turn to our usual cautionary statement regarding forward-looking statements first, and then please turn to Slide 3. Today, I want to leave you with 4 key things. Firstly, GSK is now a focused global biopharma company with a unique strategy focused on the prevention and treatment of disease.
We are a world leader in infectious diseases with an
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |